A Maryland man, Todd Engel, is suing Novo Nordisk after becoming legally blind, alleging that the company failed to warn about the potential risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with Ozempic, a drug prescribed for Type 2 diabetes. Engel’s lawsuit claims that despite evidence of NAION cases from clinical trials, the drug’s label did not include this risk, impacting his vision and life significantly. Novo Nordisk maintains that NAION is not an adverse reaction to Ozempic and emphasizes the importance of healthcare consultations regarding treatment options.
